|
|
||||||||
1 Service de Physiologie-Explorations Fonctionnelles, Centre Hospitalier Universitaire Cochin, Assistance Publique, Hôpitaux de Paris, Université Paris 5, 75014 Paris; 2 Laboratoire d'Immunologie Biologique, Faculté de Médecine Cochin, Université Paris 5, 75014 Paris; 3 Unité 408, Institut National de la Santé et de la Recherche Médicale, 75018 Paris; and 4 Service de Réanimation Pédiatrique, Hôpital Robert Debré, Assistance Publique, Hôpitaux de Paris, 75019 Paris, France
| |
ABSTRACT |
|---|
|
|
|---|
Nitric oxide (NO) is synthesized from L-arginine by the Ca2+/calmodulin-sensitive endothelial NO synthase (NOS) isoform (eNOS). The present study assesses the role of Ca2+/calmodulin-dependent protein kinase II (CaMK II) in endothelium-dependent relaxation and NO synthesis. The effects of three CaMK II inhibitors were investigated in endothelium-intact aortic rings of normotensive rats. NO synthesis was assessed by a NO sensor and chemiluminescence in culture medium of cultured porcine aortic endothelial cells stimulated with the Ca2+ ionophore A23187 and thapsigargin. Rat aortic endothelial NOS activity was measured by the conversion of L-[3H]arginine to L-[3H]citrulline. Three CaMK II inhibitors, polypeptide 281-302, KN-93, and lavendustin C, attenuated the endothelium-dependent relaxation of endothelium-intact rat aortic rings in response to acetylcholine, A23187, and thapsigargin. None of the CaMK II inhibitors affected the relaxation induced by NO donors. In a porcine aortic endothelial cell line, KN-93 decreased NO synthesis and caused a rightward shift of the concentration-response curves to A23187 and thapsigargin. In rat aortic endothelial cells, KN-93 significantly decreased bradykinin-induced eNOS activity. These results suggest that CaMK II was involved in NO synthesis as a result of Ca2+-dependent activation of eNOS.
endothelial function; nitric oxide; protein phosphorylation; signal transduction; thapsigargin
| |
INTRODUCTION |
|---|
|
|
|---|
IN ENDOTHELIAL
CELLS, stimulation of muscarinic M1 receptors by
acetylcholine (ACh) results in the activation of phospholipase C-
1, followed by a transient increase in the formation
of inositol 1,4,5-trisphosphate
[Ins(1,4,5)P3] and diacylglycerol
(2). The production of
Ins(1,4,5)P3 is considered as an initial event leading to Ca2+ release from intracellular stores that
precedes a steady or oscillating plateau phase resulting from a more
prolonged transmembranous Ca2+ influx (16). A
potential target of increased intracellular free Ca2+
concentration ([Ca2+]i) is the endothelial
nitric oxide (NO) synthase (NOS) isoform (eNOS).
Ca2+-mediated activation of eNOS requires the ubiquitous
Ca2+-binding protein calmodulin (49, 11) when
calmodulin inhibitors do not influence the relaxant response to
exogenous NO (42, 37, 50). Furthermore, the endoplasmic
reticulum Ca2+-ATPase inhibitor thapsigargin, which induces
an increase in [Ca2+]i, triggers NO-dependent
relaxation in vascular tissue (32). Thus the increase in
[Ca2+]i results in the reversible formation
of the Ca2+/calmodulin complex, which binds to eNOS,
stimulating its activity (19). Unstimulated endothelial
cells continuously produce NO, suggesting that the intracellular
Ca2+ level under resting conditions is sufficient for basal
NO synthesis. In endothelial cells, the main signal transduction
pathway of agonist-stimulated eNOS activation depends on
Ca2+/calmodulin. However, NO synthesis can be, at least in
part, regulated by serine/threonine kinases, including cAMP-dependent
protein kinase (9, 7), protein kinase C (36,
26), and protein kinase B/Akt (20, 14). Although
eNOS contains consensus sequences for phosphorylation by
serine/threonine kinases, its regulation by Ca2+-dependent
and/or Ca2+-independent phosphorylation remains to be
specified. Ca2+/calmodulin-dependent protein kinase II
(CaMK II) is a ubiquitous Ca2+/calmodulin-dependent enzyme
involved in various Ca2+-mediated mechanisms. Its
relationship with neuronal NOS (nNOS) has been previously established
by Nakane et al. (35). Although Deli et al.
(13) showed that CaMK II was expressed in endothelial cells, the link between CaMK II and NO synthesis in the endothelium remains largely unknown. We hypothesized that CaMK II might modulate Ca2+-mobilizing agent-dependent eNOS activity. The role of
CaMK II in rat aorta endothelium-dependent relaxation was investigated by pretreatment with CaMK II inhibitors. Furthermore, we studied the
interaction between Ca2+-induced NO production and CaMK
II-dependent phosphorylation by measuring NO release and eNOS activity
in a cultured porcine aortic endothelial cell (PAEC) line and rat
aortic endothelial cells pretreated with CaMK II inhibitors.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Drugs.
Reagents were from Sigma and RBI, distributed by Sigma (Saint-Quentin
Fallavier, France), unless otherwise stated. Polypeptide 281-302
(P281-302) bound calmodulin and was a potent inhibitor (IC50 = 80 nM) of exogenous substrate phosphorylation
(12). KN-93 was an inhibitor of CaMK II activation
(Ki = 0.37 µM) (45). Its
related compound, KN-92, does not show any CaMK II inhibitory activity.
Lavendustin C (Calbiochem; Meudon, France) is a potent inhibitor of
CaMK II (IC50 = 200 nM). Lavendustin C has
noncompetitive inhibitory action on the tyrosine kinase ATP binding
site and uncompetitive inhibitory action on the peptide binding site
(3). P281-302 was dissolved in desoxygenated
bidistilled water. KN-93, KN-92, and lavendustin C were dissolved in
DMSO to prepare a stock solution of 0.01 M. Phenylephrine hydrochloride
(
1-adrenoreceptor agonist), acetylcholine chloride
(muscarinic agonist), Ca2+ ionophore A23187, sodium
nitroprusside (NO donor), and
N
-nitro-L-arginine methyl ester
hydrochloride (L-NAME; analog of arginine and competitive
isozyme-nonselective NOS inhibitor) were made up in bidistilled
deionized water. Thapsigargin (Calbiochem) was dissolved in DMSO. Each
was made fresh daily and protected from light. All other drugs were
dissolved in bidistilled deionized water except indomethacin, which was
dissolved in ethanol. Further dilutions were made in Krebs solution for
in vitro experiments. The drug solutions were prepared each day from
dry powder.
Tissue preparation and tension measurement. All animal procedures were applied in accordance with the European Directive for Animal Experiments 86/609 (Centre National de la Recherche Scientifique; Paris, France). At the time of experimentation, adult male Sprague-Dawley rats (251-275 g, Charles River; Saint-Aubin Les Elbeufs, France) were anesthetized with thiopental sodium (Nesdonal; 80 mg/kg ip) and heparinized (100 IU ic). A thoracotomy was performed, and the aorta was excised en bloc in cold Krebs balanced salt solution [composed of (in mM) 118 NaCl, 5.9 KCl, 1.2 MgSO4 · 7H2O, 1.2 NaH2PO4 · 2H2O, 2.5 CaCl2 · 2H2O, 25.5 NaHCO3, and 5.6 D-glucose] containing 1 mM indomethacin. The thoracic aorta of internal diameter 2.5 ± 0.2 mm was isolated clean of adherent fat and connective tissue and cut into rings of 3.0 mm in length. The vessel was gently handled to avoid stretching and endothelial damage. Two L-shaped stainless steel wires were inserted into the arterial lumen, and the rings were suspended in a 20-ml tissue bath. One stainless steel holder was attached to the chamber, and the other holder was attached to an isometric force-displacement transducer (Emka Technologie; Paris, France). The temperature of the organ chambers was kept constant at 37°C in Krebs buffer solution gassed with 95% O2-5% CO2 (Air Liquide Santé; Paris, France). The rings were set at an initial resting tension of 1.5 g (the resting tension previously determined to be the optimal tension for length development in response to 60 mM KCl) and allowed to equilibrate for 60 min, the rings being repeatedly washed every 15 min. Verification of endothelium integrity was performed by testing the vascular relaxation produced in phenylephrine (0.1 µM)-precontracted rings by the endothelium-dependent vasodilator ACh (0.1 µM). In experiments with endothelium-denuded rat aortic rings, the endothelial cell layer was removed by rubbing the luminal surface of the vessel with a cotton swab. After equilibration, the vascular rings were submaximally precontracted with phenylephrine (1 µM), and a stepwise pharmacological sequence was initiated.
Characterization of the pharmacological responsiveness of aortic
rings.
At the plateau phase, concentration-relaxation curves to ACh
(0.001-10 µM), Ca2+ ionophore A23187 (0.01-100
µM), and thapsigargin (0.001-10 µM) were constructed by
increasing the concentration in the organ chamber in cumulative
increments after a steady-state response had been reached with each
increment on precontracted rings. After the highest concentration of
ACh, the rings were totally relaxed by sodium nitroprusside (10 µM).
In preincubation experiments, CaMK II inhibitors were added to the bath
at the plateau phase, and relaxation was proceeded after equilibration
with the tissue for 15 min. Two concentrations of
P281-302, KN-93, and lavendustin C were administrated,
corresponding to 10
6 and 10
7 M in a 20-ml
organ chamber for P281-302 and lavendustin C and to
10
5 and 10
6 M for KN-93. KN-93 and
lavendustin C were also added at
10
5-10
3 M to assess their effect at
high concentration in endothelium-denuded vascular rings. Controls were
determined by the addition of vehicle (0.01% DMSO) or KN-92 (1 µM).
Histology. Endothelium integrity was assessed by postpharmacological challenge histology analysis. Tissues were harvested, fixed in 10% neutral buffered formaldehyde, embedded in paraffin, and sectioned. Histological sections (5 µm thick) were stained with hematoxylin and eosin (Sigma) and examined.
PAEC culture. All the reagents used for cell culture were from GIBCO-BRL (Cergy-Pontoise, France) if not otherwise specified. The PAEC line established by Malassagne et al. (27) was a gift from Dr. Bernard Weill (Laboratoire d'Immunologie Biologique, Hôpital Cochin; Paris, France). PAECs were cultured in 25-cm2 Primaria dishes (Polylabo; Paris, France) in RPMI 1640 medium-glutamax-1 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml amphotericin B, and 10% fetal bovine serum. The cultures were incubated at 37°C in a humid atmosphere with 5% CO2. When cells reached confluence, they were detached by incubation with 0.05% trypsin-EDTA in RPMI 1640 medium-glutamax-1 for 3 min at 37°C, centrifuged at 300 g for 10 min, suspended in fresh complete medium, and further cultured under the same conditions. Cells were characterized as endothelial cells by their morphology, their ability to take up acetylated low-density lipoproteins (34), the detection of von Willebrand factor (41), and the expression of E-selectin (27).
Cell stimulation.
At least four sets of transfected cells (passages 29 and
30) were tested. The cells were subcultured in 24-well
flat-bottom culture plates (105 cells/well) during 24 h to reach confluence. The culture medium was removed, and the cells
were washed once and equilibrated in isotonic phosphate buffer (pH 7.4)
containing (in mM) 8 Na2HPO4, 1.5 KH2PO4, 137 NaCl, 2.7 KCl, 0.9 CaCl2,1 MgCl2, and 1 indomethacin oxygenated
with 95% O2-5% CO2 (Air Liquide Santé).
For real-time NO measurements, the sensor probe was inserted vertically
into a well with confluent cells, the sensor membrane was positioned 50 µM above the monolayer by using a manual micromanipulator, and the
well was sealed. To investigate the response to the agonists, the cells
were stimulated with either A23187 (5 × 10
8-10
5 M) or thapsigargin (5 × 10
9-10
5 M). The effect of CaMK II was
evaluated on the concentration-response curve for A23187 or
thapsigargin of cells previously incubated with KN-93 during 30 min.
For nitrate and nitrite (NOx) measurements, the cells were
incubated with KN-93 (1 µM) or KN-92 (1 µM). After the cells were
incubated for 30 min, they were stimulated by the Ca2+
ionophore A23187 (0.1, 1, and 10 µM) or thapsigargin (0.1, 1, and 10 µM). The samples of effluent were then withdrawn from the culture
well and immediately centrifuged at 300 g and 0°C for 10 min. The NOx concentration was determined in the
supernatant by chemiluminescence.
Rat aortic endothelial cell culture. The isolation of primary rat aortic cells was achieved according to the method of McGuire et al. (29). Cells were placed on a substrate including laminin and cultured in RPMI 1640 medium supplemented with 20% fetal calf serum. They were characterized by the detection of von Willebrand factor (41) and their ability to uptake acetylated low-density lipoproteins (34).
Cell stimulation. Cells were subcultured in six-well flat-bottom culture plates (4 × 105 cells/well) and incubated with KN-93 (1 µM) before stimulation with bradykinin (0.1 mM). The cells were detached by incubation with 0.05% trypsin-EDTA, centrifuged at 300 g for 10 min, and suspended in Tris · HCl (50 mM, pH 7.4) with EGTA (0.1 mM), EDTA (0.1 mM), leupeptin (1 µM), aprotinin (1 µM), and PMSF (1 µM) to measure eNOS activity.
NOx measurement. The NOx content in the culture medium was determined by measuring NO based on a gas phase chemiluminescent reaction between NO and ozone with a NO analyzer (model 280, Sievers Intruments; Boulder, CO) (31). Nitrite and nitrate were reduced by vanadium and hydrochloric acid at 90°C. NO release in the headspace was purged from the solution by an inert gas for subsequent detection by chemiluminescence. Raw data were recorded with a NO analysis liquid program (Sievers Intruments), and the peaks were integrated. The sample concentrations were computed by using a previously determined calibration curve.
Electrochemical detection of NO. S-nitroso-N-acetyl penicillamine (SNAP), CuCl, EDTA, and NaOH were obtained from Sigma-Aldrich and Fluka. All the solutions were dissolved in desoxygenated bidistilled water. Amperometric measurements of NO released were quantified with a Clark-type electrode (2 mm platinum disk NO sensor, Iso-NOP, World Precision Instruments; Stevenage, UK) connected to a Iso Mark II NO meter (World Precision Instruments). The newly developed electrode has a high selectivity for NO and a detection sensitivity of 1 nM. The principles of measurement have previously been described (44). NO diffusing through the gas-permeable membrane is oxidized at the working platinum electrode. The resulting redox current is proportional to the concentration of NO gas in the aqueous solution. The output current was recorded with the constant laboratory temperature kept constant. Calibration of the electrode was performed daily according to the procedure described by Zhang et al. (52). The NO sensor was immersed in saturated CuCl solution. After stabilization, a known volume of the SNAP solution (final concentration of 10, 20, 50, 100, and 200 nM) was then added, and the response was monitored. Measurements of NO were performed under constant stirring in glass vials sealed with a septum. Linear calibration curves were obtained from the resulting calibration plot.
eNOS activity. NOS activity was measured by the conversion of L-[3H]arginine to L-[3H]citrulline according to the methods described by Bredt et al. (8). Enzyme extract (25 µl) was incubated in the buffer [50 mM HEPES (pH 7.4), 0.5 mM NADPH, 5 µM FAD, 5 mM tetrahydrobiopterin, 1.25 mM CaCl2, and 10 µg calmodulin per ml] and 50 nM L-[3H]arginine. The enzymatic assay was terminated by the addition of 2 ml of ice-cold 20 mM HEPES (pH 5.5)-2 mM EDTA and was applied to 1-ml columns of Dowex-50W X8 (Bio-Rad). L-[3H]citrulline was eluted with 2 ml of deionized water and quantified by liquid scintillation spectroscopy.
CaMK II-
immunoblot analysis.
All reagents were from Bio-Rad (Marnes la coquette, France). Whole cell
lysate was prepared from nonstimulated cells. Cells were detached as
previously described and suspended in PBS. After centrifugation,
harvested cells were homogenized in lysis buffer [50 mM Tris (pH 8.1),
1 mM EDTA, 0.2 mM sodium orthovanadate, 1 µM leupeptin and pepstatin,
and 7 µM PMSF] and ultrasonicated. Whole cell lysates were added to
SDS sample buffer [125 mM Tris (pH 6.8), 4% SDS, 10% glycerol,
0.01% bromophenol blue, and 2%
-mercaptoethanol], boiled for 5 min, and separated on a SDS-PAGE gel according to the method of Laemmli
(25). After the migration, the proteins were transferred
on nitrocellulose membranes in semidry transfer buffer [25 mM Tris (pH
7.5), 200 mM glycine, and 20% methanol]. The blots were blocked in
1% bovine serum albumin, 25 mM Tris (pH 7.5), 150 mM NaCl, and 0.05%
Tween 20 and incubated with CaMK II antibodies (Transduction
Laboratories; Lexington, UK) for 30 min at 37°C. After being washed,
the membranes were incubated with horseradish peroxidase-conjugated
anti-mouse IgG and developed according to the enhanced
chemiluminescence immunodetection procedure (Amersham Pharmacia
Biotech; Orsay, France).
Data analysis.
All responses to phenylephrine were expressed as force (in g).
Responses to vasodilator agents were expressed as a percentage of
maximal relaxation. In the endothelium-intact vessels, the effects of
CaMK II inhibitors were measured on two rings for each aorta and the
values were averaged. For all experiments, n is the number
of rat aorta studies. Data are expressed as means ± SE of
n number of experiments. Results were analyzed using two-way ANOVA with repeated measures to compare the effects of inhibitors versus control with increasing concentrations of ACh. When the F-value for an effect was globally significant, comparisons
were made using the Mann-Whitney U-test. The NOx
concentration was normalized for cell number, and the results were
expressed as the content of NO release (in nM) per 105
cells. The cell counts were obtained manually using a hemocytometer (Neubauer type), with viabilities determined by trypan blue dye exclusion. The cells were counted after experimentation.
NOx measurements were realized twice and averaged, and
n corresponds to the number of sets analyzed. Statistical
evaluation of the difference between pretreated PAECs and the control
was assessed with Student's two-tailed t-test. All
statistical tests were considered significant for an
-level below
0.05.
| |
RESULTS |
|---|
|
|
|---|
Effects of CaMK II inhibitors on endothelium-dependent relaxation
to ACh.
In precontracted endothelium-intact aortic rings, ACh
(10
8-10
5 M) induced
concentration-dependent relaxation (EC50 = 2.57 ± 0.13 × 10
7 M, n = 8). CaMK II
inhibitors (1 µM P281-302, 1 µM KN-93, and 1 µM lavendustin
C) shifted to the right the ACh concentration-relaxation curves
(EC50 = 4.80 ± 0.24 × 10
7,
7.67 ± 0.31 × 10
7, and 5.98 ± 0.30 × 10
7 M, respectively, n = 5).
6 M and by
14 ± 6% and 19 ± 4% for 0.1 and 1 µM, respectively, at
an ACh concentration of 10
5 M (P < 0.05, n = 6; Fig. 1).
|
6 M
and by 20 ± 2% and 28 ± 6% for 1 and 10 µM,
respectively, at an ACh concentration of 10
5 M
(P < 0.05, n = 5). Its inactive
analog, KN-92 (1 µM), did not affect the ACh-induced relaxation (Fig.
2).
|
6 M and by
14 ± 7% and 14 ± 5% for 0.1 and 1 µM, respectively, at
an ACh concentration of 10
5 M (P < 0.05, n = 5; Fig. 3).
|
Effects of CaMK II inhibitors on endothelium-dependent relaxation
to A23187 and thapsigargin.
In precontracted endothelium-intact aortic rings, A23187
(10
7-10
4 M) induced
concentration-dependent relaxation (EC50 = 9.33 ± 0.23 × 10
7 M, n = 6). KN-93 (1 µM) shifted to the right the A23187 concentration-relaxation curves
(EC50 = 6.46 ± 0.30 × 10
6 M,
n = 5).
6 M and by 22 ± 3% at an A23187 concentration
of 10
5 M (P < 0.05, n = 6). Its inactive analog, KN-92 (1 µM), did not affect the
A23187-induced relaxation (Fig. 4).
|
8-10
5 M) induced
concentration-dependent relaxation (EC50 = 1.91 ± 0.30 × 10
7 M, n = 5). KN-93 (1 µM) shifted to the right the thapsigargin concentration-relaxation
curves (EC50 = 2.45 ± 0.28 × 10
7 M, n = 5).
Treatment of aortic rings with KN-93 (1 µM) decreased the
thapsigargin-induced relaxation by 22 ± 8% at a thapsigargin
concentration of 10
6 M and by 13 ± 5% at a
thapsigargin concentration of 10
5 M (P < 0.05, n = 6). Its inactive analog, KN-92 (1 µM), did
not affect the thapsigargin-induced relaxation (Fig.
5).
|
Effects of CaMK II inhibitors on exogenous NO-induced relaxation. Sodium nitroprusside (10 µM) totally relaxed the aortic ring (98 ± 2%). Neither CaMK II inhibitors nor the inactive analog KN-92 at all concentrations have inhibitory action on sodium nitroprusside (10 µM) relaxation (data not shown). None of the three CaMK II inhibitors evoked spontaneously relaxation in endothelium-intact or -denuded vascular rings.
Effect of CaMK II inhibitors on endothelium-denuded and -intact
aortic ring contraction.
In endothelium-denuded aortic rings, the three CaMK II inhibitors did
not have an inhibitory action on phenylephrine (1 µM) contraction. In
endothelium-intact aortic rings, both P281-302 (1 µM) and KN-93
(10 µM) did not alter phenylephrine (an
1-adrenoreceptor agonist) contraction. However,
lavendustin C at a concentration of 10 µM induced an additional
contraction of endothelium-intact aortic rings precontracted with
phenylephrine by 18 ± 7% (P < 0.05, n = 5). The lavendustin C-induced increase in vascular
tone was inhibited by L-NAME (10 µM).
Immunoblot characterization of CaMK II-
.
After SDS-PAGE and semidry transfer, membrane extracts of PAECs were
revealed with anti-CaMK II isotype IgG1. IgG1
bound to 52-kDa antigens. The same band was revealed on the control
(rat brain lysate; Fig. 6).
|
Effect of the CaMK II inhibitor KN-93 on NO production.
In cultured endothelial cells, A23187 (5 × 10
8-10
5 M) and thapsigargin (5 × 10
9-10
5 M) induced NO release
(EC50 = 9.12 × 10
7 and 7.24 × 10
7 M, respectively). Preincubation with
L-NAME (10 µM) inhibited agonist-induced NO release.
KN-93 (1 µM) shifted to the right the concentration-response curve of
A23187- and thapsigargin-induced NO release (EC50 = 1.26 × 10
6 and 9.77 × 10
7 M,
respectively; Fig. 7).
|
Decreased NOx concentration by KN-93 on cultured endothelial cells stimulated by A23187 or thapsigargin. Stimulation of endothelial cells with the Ca2+ ionophore A23187 (1 and 10 µM) increased the NOx concentration in PAEC culture medium by 1,477 ± 51 and 2,075 ± 111 nM/105 cells, respectively. L-NAME (10 µM) inhibited the NOx production. The background NOx concentration from the isotonic phosphate buffer was 114 ± 20 nM/105 cells.
KN-93 (1 µM) reduced the NOx concentration in culture medium of PAECs stimulated with A23187 (1 and 10 µM) by 26 ± 5% and 10 ± 4%, respectively (P < 0.05, n = 4; Fig. 7A). CaMK II inhibitor reduced the NOx concentration in the culture medium of PAECs stimulated with thapsigargin (1 and 10 µM) by 22 ± 4% and 17 ± 5%, respectively (P < 0.05, n = 4; Fig. 7B).Decreased rat aortic endothelial cell eNOS activity by KN-93.
Bradykinin-dependent eNOS activity as assessed by the conversion of
L-[3H]arginine to
L-[3H]citrulline was reduced to 43 ± 3% by KN-93 (1 µM). Note that eNOS activity in rat aortic
endothelial cells was totally inhibited by L-NAME (Fig.
8).
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results provide evidence that three different CaMK II inhibitors decreased endothelium-dependent relaxation elicited by ACh in normotensive rats. None of the CaMK II inhibitors inhibited relaxation induced by NO donors. KN-93 inhibited both receptor-independent and -dependent agonist-induced relaxation. The effects of CaMK II inhibitors were confirmed in both the PAEC line and rat aortic endothelial primary cultured cells. In the former, KN-93 significantly decreased the NO release in response to both the Ca2+ ionophore A23187 and thapsigargin. In the latter, KN-93 markedly reduced bradykinin-stimulated eNOS activity. Our results suggest that NO synthesis is dependent on CaMK II. The involvement of CaMK II in porcine endothelial NO production and rat NO-dependent relaxation characterized by the response to P281-302, KN-93, and lavendustin C on endothelium-dependent relaxation may be due to 1) an interference with ACh-induced Ca2+ release, 2) a direct effect on eNOS and/or calmodulin phosphorylation, and 3) an inhibition of NO-independent vascular smooth muscle relaxation.
To avoid bias due to nonspecific inhibitory effects of the compounds, our experiments were repeated with three structurally different CaMK II inhibitors. The synthetic polypeptide P281-309 contains the calmodulin-binding site (amino acids 290-309) and the autophosphorylation (Thr286) of CaMK II and therefore inhibits CaMK II by blocking Ca2+/calmodulin activation and the enzyme active site. KN-93 and lavendustin C inhibit CaMK II in a competitive fashion against calmodulin by decreasing the autophosphorylation of CaMK II. The effects of KN-93 on other CaMK isoforms remain unknown. CaMK II and eNOS represent two Ca2+/calmodulin-dependent enzymes. Their activation follows the agonist-induced increase in [Ca2+]i. Our results showing that CaMK II inhibitors decreased ACh-induced relaxation suggest that CaMK II inhibitors may alter the Ca2+ release induced by ACh. However, a specific interference at the level of the muscarinic M1 receptors only may be excluded because KN-93 decreased receptor-independent Ca2+ ionophore A23187-induced rat aorta relaxation, and, in PAECs, the [Ca2+]i increase-dependent eNOS activation elicited by A23187 was attenuated by pretreatment with CaMK II inhibitor. These findings are consistent with previous results showing that, in endothelial cells, KN-93 and lavendustin C did not modify basal [Ca2+]i, unlike the calmodulin antagonist-provoked dose-dependent increases in [Ca2+]i (48). Furthermore, our results with thapsigargin, which induced an increase in the [Ca2+]i by mobilization from Ins(1,4,5)P3 Ca2+ stores (15), suggest that CaMK II was not involved in endoplasmic reticulum Ca2+- ATPase activity and did not inhibit Ca2+ release from internal stores. In concert, our data support the hypothesis that CaMK II is involved downstream of the mobilization of intracellular Ca2+ stores directly on eNOS activation.
As with other NOS isoforms, eNOS might represent a direct protein substrate for CaMK II (43). However, Bredt et al. (7) reported no effect on soluble nNOS, whereas Nakane et al. (35) showed that CaMK II-induced phosphorylation of nNOS decreased its activity. Alternatively, Toda et al. (47) have shown that, in the cerebral artery, NO-mediated relaxation was attenuated by an inhibitor of CaMK II. This different behavior may be explained by the particular localization of eNOS in endothelial cells, where it is initially targeted to the membrane fraction (38) and subsequently translocated from the membrane to the soluble fraction after stimulation of the cells (30). This particular property of eNOS is partly due to the presence of NH2-terminal myristoylation and palmitoylation (10, 39). However, these posttranslational modifications are not sufficient for membrane localization, and phosphorylation of the enzyme is an alternative mechanism for the reversible association of the enzyme with membrane phospholipids (28). Alternatively, in cultured endothelial cells, agonist-induced eNOS phosphorylation increases its sensitivity to activation by Ca2+ (17). Thus pretreatment of endothelial cells with CaMK II inhibitors might either inhibit the translocation of eNOS or enhance the desensitization to Ca2+. Our results showing the decrease of eNOS activity in parallel of the reduction of NO-dependent relaxation suggest that CaMK II directly phosphorylates eNOS protein. This hypothesis was recently confirmed by Fleming et al. (18), who demonstrated that porcine eNOS activity depends on serine (Ser1177) eNOS phosphorylation by CaMK II. Their biochemical approach, together with our results, demonstrate the effect of CaMK II inhibitors on PAEC NO production and rat aorta endothelium-dependent relaxation after stimulation by Ca2+-mobilizing agents.
Our results with sodium nitroprusside suggest that CaMK II did not affect soluble guanylyl cyclase activity. These findings are consistent with those of Toda et al. (47), who showed that the response to exogenous NO was unaffected by CaMK II inhibitors, whereas the agonist-dependent NO-induced increase in cGMP concentration was reduced. Thus ACh-induced relaxation was attenuated by CaMK II inhibitors, indicating their roles in NO synthesis. Furthermore, CaMK II inhibitors did not spontaneously relax endothelium-denuded rat aortic rings, suggesting that an endothelium-insensitive effect may be ruled out.
CaMK II has been implicated in the regulation of tonic vascular smooth
muscle contractility mediated by myosin light chain phosphorylation
(1, 46, 40). However, the CaMK II inhibitor KN-93 did not
impair the contraction in response to the
1-adrenoreceptor agonist phenylephrine
(24). Our results with endothelium-denuded aortic rings
confirm that vascular smooth muscle was insensitive to KN-93. However,
a high concentration of lavendustin C slightly increased
endothelium-intact contraction, suggesting that lavendustin C can
increase vasoconstrictor tone by inhibiting basal NO activity. This
hypothesis was confirmed by the absence of the lavendustin C
contractile effect in the presence of L-NAME.
In conclusion, P281-302, KN-93, and lavendustin C, three structurally different CaMK II inhibitors, decreased the endothelium-dependent relaxation of isolated vessels and NO production by endothelial cells. These results suggest that, in addition to protein kinases A, B, and C, CaMK II was involved in NO synthesis. The agonist-induced [Ca2+]i increase leads to Ca2+/calmodulin-mediated eNOS activation but may also potentiate the NO synthesis by CaMK II-dependent phosphorylation of eNOS. Thus CaMK II modulates, at least in part, the activity and/or the intracellular localization of eNOS and may add another level of regulation in endothelium-dependent relaxation, which is of pharmacological interest in cardiovascular therapy.
| |
ACKNOWLEDGEMENTS |
|---|
The authors are grateful to S. Chouzenoux for technical assistance.
| |
FOOTNOTES |
|---|
This work was supported by a grant from Air Liquide Santé.
Address for reprint requests and other correspondence: A. T. Dinh-Xuan, Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, 27, Rue Du Faubourg Saint-Jacques, 75679 Paris cedex 14, France (E-mail: anh-tuan.dinh-xuan{at}cch.ap-hop-paris.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published January 30, 2003;10.1152/ajpheart.00932.2001
Received 25 October 2001; accepted in final form 8 January 2003.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abraham, ST,
Benscoter HA,
Schworer CM,
and
Singer HA.
A role for Ca2+/calmodulin-dependent protein kinase II in the mitogen-activated protein kinase signaling cascade of cultured rat aortic vascular smooth muscle cells.
Circ Res
81:
575-584,
1997
2.
Adams, DJ,
Barakeh J,
Laskey R,
and
Van Breemen C.
Ion channels and regulation of intracellular calcium in vascular endothelial cells.
FASEB J
3:
2389-2400,
1989[Abstract].
3.
Agbotounou, WK,
Umezawa K,
Jacquemin-Sablon A,
and
Pierre J.
Inhibition by two lavendustins of the tyrosine kinase activity of pp60F527 in vitro and in intact cells.
Eur J Pharmacol
269:
1-8,
1994[ISI][Medline].
4.
Anderson, ME,
Braun AP,
Wu Y,
Lu T,
Wu Y,
Schulman H,
and
Sung RJ.
KN-93, an inhibitor of multifunctional Ca2+/calmodulin-dependent protein kinase, decreases early after depolarizations in rabbit heart.
J Pharmacol Exp Ther
287:
996-1006,
1998
5.
Berk, BC,
Corson MA,
Peterson TE,
and
Tseng H.
Protein kinases as mediators of fluid shear stress stimulated signal transduction in endothelial cells: a hypothesis for calcium-dependent and calcium-independent events activated by flow.
J Biomech
28:
1439-1450,
1995[ISI][Medline].
6.
Berridge, MJ.
Inositol trisphosphate and calcium signaling.
Nature
361:
315-325,
1993[Medline].
7.
Bredt, DS,
Ferris CD,
and
Snyder SH.
Nitric oxide synthase regulatory sites. Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites.
J Biol Chem
267:
10976-10981,
1992
8.
Bredt, DS,
and
Snyder SH.
Isolation of nitric oxide, a calmodulin-requiring enzyme.
Proc Natl Acad Sci USA
87:
682-685,
1990
9.
Brune, B,
and
Lapetina EG.
Phosphorylation of nitric oxide synthase by protein kinase A.
Biochem Biophys Res Commun
181:
921-926,
1991[ISI][Medline].
10.
Busconi, L,
and
Michel T.
Endothelial nitric oxide synthase. N-terminal myristoylation determines subcellular localization.
J Biol Chem
268:
8410-8413,
1993
11.
Busse, R,
and
Mulsch A.
Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin.
FEBS Lett
265:
133-136,
1990[ISI][Medline].
12.
Colbran, RJ,
Fong YL,
Schworer CM,
and
Soderling TR.
Regulatory interactions of the calmodulin-binding, inhibitory, and autophosphorylation domains of Ca2+/calmodulin-dependent protein kinase II.
J Biol Chem
263:
18145-18151,
1988
13.
Deli, MA,
Joo F,
Krizbai I,
Lengyel I,
Nunzi MG,
and
Wolff JR.
Ca2+/calmodulin-stimulated protein kinase II is present in primary cultures of cerebral endothelial cells.
J Neurochem
60:
1960-1963,
1993[ISI][Medline].
14.
Dimmeler, S,
Fleming I,
Fisslthaler B,
Hermann C,
Busse R,
and
Zeiher AM.
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.
Nature
399:
601-605,
1999[Medline].
15.
Dolor, RJ,
Hurwitz LM,
Mirza Z,
Strauss HC,
and
Whorton AR.
Regulation of extracellular calcium entry in endothelial cells: role of intracellular calcium pool.
Am J Physiol Cell Physiol
262:
C171-C181,
1992
16.
Falcone, JC,
Kuo L,
and
Meininger GA.
Endothelial cell calcium increases during flow-induced dilation in isolated arterioles.
Am J Physiol Heart Circ Physiol
264:
H653-H659,
1993
17.
Fleming, I,
and
Busse R.
Tyrosine phosphorylation and bradykinin-induced signaling in endothelial cells.
Am J Cardiol
80:
102A-109A,
1997[Medline].
18.
Fleming, I,
Fisslthaler B,
Dimmeler S,
Kemp BE,
and
Busse R.
Phosphorylation of Thr495 regulates Ca2+/calmodulin-dependent endothelial nitric oxide synthase activity.
Circ Res
88:
E68-E75,
2001[ISI][Medline].
19.
Förstermann, U,
Closs EI,
Pollock JS,
Nakane M,
Schwarz P,
Gath I,
and
Kleinert H.
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
Hypertension
23:
1121-1131,
1994
20.
Fulton, D,
Gratton JP,
McCabe TJ,
Fontana J,
Fujio Y,
Walsh K,
Franke TF,
Papapetropoulos A,
and
Sessa WC.
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.
Nature
399:
597-601,
1999[Medline].
21.
Gailly, P.
Ca2+ entry in CHO cells, after Ca2+ stores depletion, is mediated by arachidonic acid.
Cell Calcium
24:
293-304,
1998[ISI][Medline].
22.
Hwang, J,
Bragado MJ,
Duan RD,
and
Williams JA.
Protein phosphatase inhibitors potentiate Ca2+/calmodulin-dependent protein kinase II activity in rat pancreatic acinar cells.
Biochem Biophys Res Commun
225:
520-524,
1996[ISI][Medline].
23.
Illiano, S,
Nagao T,
and
Vanhoutte PM.
Calmidazolium, a calmodulin inhibitor, inhibits endothelium-dependent relaxations resistant to nitro-L-arginine in the canine coronary artery.
Br J Pharmacol
107:
387-392,
1992[ISI][Medline].
24.
Kim, I,
Je HD,
Gallant C,
Zhan Q,
Riper DV,
Badwey JA,
Singer HA,
and
Morgan KG.
Ca2+-calmodulin-dependent protein kinase II-dependent activation of contractility in ferret aorta.
J Physiol
526:
367-374,
2000
25.
Laemmli, UK.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:
680-685,
1970[Medline].
26.
Li, H,
Oehrlein SA,
Wallerath T,
Ihrig-Biedert I,
Wohlfart P,
Ulshofer T,
Jessen T,
Herget T,
Förstermann U,
and
Kleinert H.
Activation of protein kinase C
and/or
enhances transcription of the human endothelial nitric oxide synthase gene.
Mol Pharmacol
53:
630-637,
1998
27.
Malassagne, B,
Taboit F,
Conti F,
Batteux F,
Atia N,
Chéreau C,
Conjeaud H,
Theron MC,
Attal J,
Braet F,
Houdebine LM,
Calmus Y,
Houssin D,
and
Weill B.
A newly established porcine aortic endothelial cell line: characterization and application to the study of human-to-swine graft rejection.
Exp Cell Res
238:
90-100,
1998[ISI][Medline].
28.
Matsubara, M,
Titani K,
and
Taniguchi H.
Interaction of calmodulin-binding domain peptides of nitric oxide synthase with membrane phospholipids: regulation by protein phosphorylation and Ca2+-calmodulin.
Biochemistry
35:
14651-14658,
1996[Medline].
29.
McGuire, PG,
and
Orkin RW.
Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata.
Lab Invest
57:
94-105,
1987[ISI][Medline].
30.
Michel, T,
Li GK,
and
Busconi L.
Phosphorylation and subcellular translocation of endothelial nitric oxide synthase.
Proc Natl Acad Sci USA
90:
6252-6256,
1993
31.
Michelakis, ED,
and
Archer SL.
The measurement of NO in biological systems using chemiluminescence.
Methods Mol Biol
100:
111-127,
1998[Medline].
32.
Moritoki, H,
Hisayama T,
Kondoh W,
and
Takeuchi S.
Thapsigargin, a Ca2+-ATPase inhibitor, relaxes rat aorta via nitric oxide formation.
Life Sci
54:
PL153-PL158,
1994[ISI][Medline].
33.
Muthalif, MM,
Benter IF,
Uddin MR,
and
Malik KU.
Ca2+/calmodulin-dependent protein kinase II
mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells.
J Biol Chem
271:
30149-30157,
1996
34.
Nagelkerke, JF,
Barto KP,
and
Van Berkel TJ.
In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells.
J Biol Chem
258:
12221-12227,
1983
35.
Nakane, M,
Mitchell J,
Förstermann U,
and
Murad F.
Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase.
Biochem Biophys Res Commun
180:
1396-1402,
1991[ISI][Medline].
36.
Ohara, Y,
Sayegh HS,
Yamin JJ,
and
Harrison DG.
Regulation of endothelial constitutive nitric oxide synthase by protein kinase C.
Hypertension
25:
415-420,
1995
37.
Okamura, T,
and
Toda N.
Inhibition by calmodulin antagonists of the neurogenic relaxation in cerebral arteries.
Eur J Pharmacol
256:
79-83,
1994[ISI][Medline].
38.
Pollock, JS,
Förstermann U,
Mitchell JA,
Warner TD,
Schmidt HH,
Nakane M,
and
Murad F.
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.
Proc Natl Acad Sci USA
88:
10480-10484,
1991
39.
Robinson, LJ,
Busconi L,
and
Michel T.
Agonist-modulated palmitoylation of endothelial nitric oxide synthase.
J Biol Chem
270:
995-998,
1995
40.
Rokolya, A,
and
Singer HA.
Inhibition of CaM kinase II activation and force maintenance by KN-93 in arterial smooth muscle.
Am J Physiol Cell Physiol
278:
C537-C545,
2000
41.
Ruggeri, ZM,
and
Ware J.
Von Willebrand factor.
FASEB J
7:
308-316,
1993[Abstract].
42.
Schini, VB,
and
Vanhoutte PM.
Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta.
J Pharmacol Exp Ther
261:
553-559,
1992
43.
Schmidt, HH,
Pollock JS,
Nakane M,
Förstermann U,
and
Murad F.
Ca2+/calmodulin-regulated nitric oxide synthases.
Cell Calcium
13:
427-434,
1992[ISI][Medline].
44.
Shibuki, K.
An electrochemical microprobe for detecting nitric oxide release in brain tissue.
Neurosci Res
9:
69-76,
1990[ISI][Medline].
45.
Sumi, M,
Kiuchi K,
Ishikawa T,
Ishii A,
Hagiwara M,
Nagatsu T,
and
Hidaka H.
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells.
Biochem Biophys Res Commun
181:
968-975,
1991[ISI][Medline].
46.
Sunagawa, M,
Yokoshiki H,
Seki T,
and
Sperelakis N.
Intracellular application of calmidazolium increases Ca2+ current through activation of protein kinase A in cultured vascular smooth muscle cells.
J Vasc Res
35:
303-309,
1998[ISI][Medline].
47.
Toda, N,
Ayajiki K,
and
Okamura T.
Effect of Ca2+/calmodulin-dependent protein kinase II inhibitors on the neurogenic cerebroarterial relaxation.
Eur J Pharmacol
340:
59-65,
1997[ISI][Medline].
48.
Watanabe, H,
Takahashi R,
Tran QK,
Takeuchi K,
Kosuge K,
Satoh H,
Uehara A,
Terada H,
Hayashi H,
Ohno R,
and
Ohashi K.
Increased cytosolic Ca2+ concentration in endothelial cells by calmodulin antagonists.
Biochem Biophys Res Commun
265:
697-702,
1999[ISI][Medline].
49.
Weinheimer, G,
and
Osswald H.
Inhibition of endothelium-dependent smooth muscle relaxation by calmodulin antagonists.
Naunyn Schmiedebergs Arch Pharmacol
332:
391-397,
1986[ISI][Medline].
50.
Win, NH,
Ishikawa T,
Saito N,
Kato M,
Yokokura H,
Watanabe Y,
Iida Y,
and
Hidaka H.
A new and potent calmodulin antagonist, HF-2035, which inhibits vascular relaxation induced by nitric oxide synthase.
Eur J Pharmacol
299:
119-126,
1996[ISI][Medline].
51.
Wu, Y,
MacMillan LB,
McNeill RB,
Colbran RJ,
and
Anderson ME.
CaM kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias.
Am J Physiol Heart Circ Physiol
276:
H2168-H2178,
1999
52.
Zhang, X,
Cardosa L,
Davies IR,
Broderick M,
and
Fein H.
Monovalent copper (Cu+) catalyzes the decomposition of SNAP stochiometrically, as demonstrated using novel micro NO sensor.
Acta Physiol Scand
167, Suppl 645:
S113-S116,
1999.
This article has been cited by other articles:
![]() |
D. Maiti, Z. Xu, and E. J. Duh Vascular Endothelial Growth Factor Induces MEF2C and MEF2-Dependent Activity in Endothelial Cells Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3640 - 3648. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Cai, D. Liu, and J. G.N. Garcia CaM Kinase II-dependent pathophysiological signalling in endothelial cells Cardiovasc Res, January 1, 2008; 77(1): 30 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Soucy, S. Ryoo, A. Benjo, H. K. Lim, G. Gupta, J. S. Sohi, J. Elser, M. A. Aon, D. Nyhan, A. A. Shoukas, et al. Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness J Appl Physiol, December 1, 2006; 101(6): 1751 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Leffler, L. Balabanova, A. L. Fedinec, and H. Parfenova Nitric oxide increases carbon monoxide production by piglet cerebral microvessels Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1442 - H1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Saraswathi, G. Wu, M. Toborek, and B. Hennig Linoleic acid-induced endothelial activation: role of calcium and peroxynitrite signaling J. Lipid Res., May 1, 2004; 45(5): 794 - 804. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||